191 related articles for article (PubMed ID: 16273353)
21. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Moy B; Goss PE
Clin Cancer Res; 2006 Aug; 12(16):4790-3. PubMed ID: 16914563
[TBL] [Abstract][Full Text] [Related]
22. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Johnston SR
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
[TBL] [Abstract][Full Text] [Related]
23. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
Johnston SR
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
[TBL] [Abstract][Full Text] [Related]
24. What clinicians need to know about antioestrogen resistance in breast cancer therapy.
Milano A; Dal Lago L; Sotiriou C; Piccart M; Cardoso F
Eur J Cancer; 2006 Nov; 42(16):2692-705. PubMed ID: 16963260
[TBL] [Abstract][Full Text] [Related]
25. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator SJ; Ahamed E; Coombes RC; Palmieri C
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Nahta R; O'Regan RM
Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
29. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
Fedele P; Calvani N; Marino A; Orlando L; Schiavone P; Quaranta A; Cinieri S
Crit Rev Oncol Hematol; 2012 Nov; 84(2):243-51. PubMed ID: 22494933
[TBL] [Abstract][Full Text] [Related]
30. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
Johnston SR
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):889s-99s. PubMed ID: 15701883
[TBL] [Abstract][Full Text] [Related]
31. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
32. Prediction of hormone sensitivity for breast cancers.
Miyoshi Y; Murase K; Saito M; Oh K
Breast Cancer; 2010 Apr; 17(2):86-91. PubMed ID: 19806427
[TBL] [Abstract][Full Text] [Related]
33. Membrane-initiated steroid signaling action of estrogen and breast cancer.
Song RX
Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
[TBL] [Abstract][Full Text] [Related]
34. Emerging strategies to overcome resistance to endocrine therapy for breast cancer.
Ziauddin MF; Hua D; Tang SC
Cancer Metastasis Rev; 2014 Sep; 33(2-3):791-807. PubMed ID: 24944077
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
Azim HA; Piccart MJ
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1255-63. PubMed ID: 20735311
[TBL] [Abstract][Full Text] [Related]
36. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
McIlroy M; McCartan D; Early S; O Gaora P; Pennington S; Hill AD; Young LS
Cancer Res; 2010 Feb; 70(4):1585-94. PubMed ID: 20145129
[TBL] [Abstract][Full Text] [Related]
37. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
Nicholson RI; Hutcheson IR; Britton D; Knowlden JM; Jones HE; Harper ME; Hiscox SE; Barrow D; Gee JM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):257-62. PubMed ID: 15860268
[TBL] [Abstract][Full Text] [Related]
38. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.
Nicholson RI; Staka C; Boyns F; Hutcheson IR; Gee JM
Endocr Relat Cancer; 2004 Dec; 11(4):623-41. PubMed ID: 15613443
[TBL] [Abstract][Full Text] [Related]
39. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
[TBL] [Abstract][Full Text] [Related]
40. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
Roop RP; Ma CX
Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]